EUVIMEDEUVIMED entdecken
Crossref

Noninvasive tests maintain high accuracy for advanced fibrosis in chronic hepatitis B patients with different nomenclatures of steatotic liver disease

Lin Chen iD, Xuemei Tao iD, Minghui Zeng, Yuqin Li, Jiaxin Han, Yuekui Wang, Yonggang Liu, Ruifang Shi, Rui Su, Liang Xu, Yuqiang Mi

Journal of Medical Virology · 2024

DOI: 10.1002/jmv.29613 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Lin Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical School of the Second People's Hospital, Tianjin Medical University, Tianjin, China. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Tianjin Health Science and Technology Project key discipline special, Tianjin Key Medical Discipline (Specialty) Construction Project, Chinese Foundation for Hepatitis Prevention and Control-Tian Qing Hepatitis Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a new nomenclature proposed in 2023. We aimed to compare the diagnostic efficacy of noninvasive tests (NITs) for advanced fibrosis under different nomenclatures in patients with chronic hepatitis B (CHB). A total of 844 patients diagnosed with CHB and concurrent steatotic liver disease (SLD) by liver biopsy were retrospectively enrolled and divided into four groups. The performances of fibrosis‐4 (FIB‐4), gamma‐glutamyl transpeptidase to platelet ratio index (GPRI), aspartate aminotransferase to platelet ratio index (APRI), and liver stiffness measurement (LSM) were compared among the four groups. The four NITs showed similar diagnostic efficacy for nonalcoholic fatty liver disease (NAFLD), MASLD, and metabolic dysfunction‐associated fatty liver disease (MAFLD) in patients with CHB with advanced fibrosis. LSM showed the most stable accuracy for NAFLD (AUC = 0.842), MASLD (AUC = 0.846), and MAFLD (AUC = 0.863) compared with other NITs ( p < 0.05). Among the four NITs, APRI (AUC = 0.841) and GPRI (AUC = 0.844) performed best in patients with CHB & MetALD ( p < 0.05). The cutoff value for GPRI in patients with CHB & MetALD was higher than that in the other three groups, while further comparisons of NITs at different fibrosis stages showed that the median GPRI of CHB & MetALD (1.113) at F3‐4 was higher than that in the CHB & MASLD group (0.508) ( p < 0.05). Current NITs perform adequately in patients with CHB and SLD; however, alterations in cutoff values for CHB & MetALD need to be noted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B, ChronicNon-alcoholic Fatty Liver DiseaseHumansLiver CirrhosisRetrospective StudiesBiomarkersBiopsyAspartate AminotransferasesROC CurveLiver

Stichwörter der Autor:innen

advanced fibrosisfatty liverhepatitis Bnoninvasive teststeatotic

Substanzen

BiomarkersAspartate Aminotransferases

Autor:innen und Institutionen

  • Clinical School of the Second People's Hospital, Tianjin Medical University, Tianjin, China.
  • Department of Hepatology, Tianjin Second People's Hospital, Tianjin, China.
  • Medical School of Chinese People's Liberation Army (PLA), Beijing, China.
  • Department of Pathology and Hepatology, the Fifth Medical Center of PLA General Hospital, Beijing, China.
  • Tianjin Research Institute of Liver Diseases, Tianjin, China.

ORCID-Profile: Lin Chen, Xuemei Tao

Förderung

  • Tianjin Health Science and Technology Project key discipline special
  • Tianjin Key Medical Discipline (Specialty) Construction Project
  • Chinese Foundation for Hepatitis Prevention and Control-Tian Qing Hepatitis Research Fund
  • Research project in key areas of TCM in Tianjin
  • National Natural Science Foundation of China

Zitieren

APA

Chen, L., Tao, X., Zeng, M., Li, Y., Han, J., Wang, Y., Liu, Y., Shi, R., Su, R., Xu, L., & Mi, Y. (2024). Noninvasive tests maintain high accuracy for advanced fibrosis in chronic hepatitis B patients with different nomenclatures of steatotic liver disease. Journal of Medical Virology. https://doi.org/10.1002/jmv.29613

Vancouver

Chen L, Tao X, Zeng M, Li Y, Han J, Wang Y, et al. Noninvasive tests maintain high accuracy for advanced fibrosis in chronic hepatitis B patients with different nomenclatures of steatotic liver disease. Journal of Medical Virology. 2024. doi:10.1002/jmv.29613

BibTeX
@article{Chen2024,
  author = {Chen, Lin and Tao, Xuemei and Zeng, Minghui and Li, Yuqin and Han, Jiaxin and Wang, Yuekui and Liu, Yonggang and Shi, Ruifang and Su, Rui and Xu, Liang and Mi, Yuqiang},
  title = {Noninvasive tests maintain high accuracy for advanced fibrosis in chronic hepatitis B patients with different nomenclatures of steatotic liver disease},
  journal = {Journal of Medical Virology},
  year = {2024},
  doi = {10.1002/jmv.29613}
}
Kostenlos starten →